

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                  |
|---|---|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |                  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>Date Submitted: March 5, 2009<br><i>(use as many sheets as necessary)</i> |   |    |   | Application Number       | 10/522,664       |
|   |   |    |   | Filing Date              | 7/31/2003        |
|   |   |    |   | First Named Inventor     | Heinz-Josef Lenz |
|   |   |    |   | Art Unit                 | 1634             |
|   |   |    |   | Examiner Name            | Carla J. Myers   |
| Sheet   | 1 | of | 3 | Attorney Docket Number   | 064189-0604      |

| U.S. PATENT DOCUMENTS |                          |   |                                |  |  |
|-----------------------|--------------------------|---|--------------------------------|--|--|
| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                             | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|                       |                          | Number-Kind Code <sup>2</sup> (if<br>known) |                                |  |  |
|                       |                          |   |                                |  |  |

| UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS |                          |  |  |  |  |
|---|--------------------------|--|--|--|--|
| Examiner<br>Initials*                         | Cite<br>No. <sup>1</sup> | U.S. Patent Application<br>Document                | Filing Date of<br>Cited Document<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|   |                          | Serial Number-Kind Code <sup>2</sup><br>(if known) |  |  |  |
|   |                          |  |  |  |  |

| FOREIGN PATENT DOCUMENTS |                          |  |                                |   |  |                |
|--------------------------|--------------------------|--|--------------------------------|---|--|----------------|
| Examiner<br>Initials*    | Cite<br>No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Documents | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|                          |                          | Country Code <sup>3</sup> Number <sup>4</sup><br>Kind Code <sup>5</sup> (if known) |                                |   |  |                |
|                          |                          |  |                                |   |  |                |

| NON PATENT LITERATURE DOCUMENTS |                          |  |  |  |                |
|---------------------------------|--------------------------|--|--|--|----------------|
| Examiner<br>Initials*           | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. |  |  | T <sup>6</sup> |
|                                 |                          |  |  |  |                |
| /CM/                            | D28                      | CHANG et al. (2008) "ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma" Cancer Sci. 100(2):278-283  |  |  |                |
| /CM/                            | D29                      | HUANG et al. (2008) "ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer" World J. Gastroenterol. 14(41):6401-6407  |  |  |                |
| /CM/                            | D30                      | ISLA et al. (2004) "Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer" Annals of Oncology 15:1194-1203  |  |  |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                               |                  |
|---|---|-------------------------------|------------------|
| Substitute for form 1449/PTO  |   | <b>Complete if Known</b>      |                  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>Date Submitted: March 5, 2009<br><br><i>(use as many sheets as necessary)</i> |   | <b>Application Number</b>     | 10/522,664       |
|   |   | <b>Filing Date</b>            | 7/31/2003        |
|   |   | <b>First Named Inventor</b>   | Heinz-Josef Lenz |
|   |   | <b>Art Unit</b>               | 1634             |
|   |   | <b>Examiner Name</b>          | Carla J. Myers   |
| <b>Sheet</b>  | 2 | <b>of</b>                     | 3                |
|   |   | <b>Attorney Docket Number</b> | 064189-0604      |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.                                   | T <sup>6</sup> |
| /CM/<br>↓                       | D31                   | KAMIKOZURU et al. (2008) "ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy" International Journal of Oncology <b>32</b> :1091-1096   |                |
|                                 | D32                   | KANG et al. (2006) "Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer" Experimental and Molecular Medicine <b>38</b> (3):320-324                                     |                |
|                                 | D33                   | KEAM et al. (2008) "Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker" BMC Cancer <b>8</b> :148, 10 pgs   |                |
|                                 | D34                   | KRIVAK et al. (2008) "Relationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer" J. Clin. Oncol. <b>26</b> (21):3598-3606 |                |
|                                 | D35                   | LIU et al. (2005) "Impact of Gene Polymorphisms on Clinical Outcome for Stage IV Melanoma Patients Treated with Biochemotherapy: An Exploratory Study" Clin. Cancer Res. <b>11</b> :1237-1246  |                |
|                                 | D36                   | MARTINEZ-BALIBREA et al. (2008) "Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer" European J. of Cancer <b>44</b> :1229-1237  |                |
|                                 | D37                   | PARE et al. (2008) "Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy" British J. Cancer <b>99</b> :1050-1055  |                |
|                                 | D38                   | PARK et al. (2006) "Effect of ERCC1 Polymorphisms and Modification by Smoking on the Survival of Non-Small Cell Lung Cancer Patients" Medical Oncology <b>23</b> (4):489-498   |                |
|                                 | D39                   | RUZZO et al. (2007) "Pharmacogenetic Profiling in Patients with Advanced Colorectal Cancer treated with First-Line FOLFOX-4 Chemotherapy" J. Clin. Oncol. <b>25</b> (10):1247-1254   |                |
|                                 | D40                   | RYU et al. (2004) "Association between polymorphism of ERCC1 and XPD and Survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy" Lung Cancer <b>44</b> :311-316   |                |
|                                 | D41                   | SMITH et al. (2007) "ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit from Paclitaxel Treatment in Addition to Platinum-Based Therapy" J. Clin. Oncol. <b>25</b> (33):5172-5179   |                |
|                                 | D42                   | STEFFENSEN et al. (2008) "Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer" Int. J. Gynecol. Cancer <b>18</b> :702-710  |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                  |
|---|---|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO  |   |    |   | <b>Complete if Known</b> |                  |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>Date Submitted: March 5, 2009<br><i>(use as many sheets as necessary)</i> |   |    |   | Application Number       | 10/522,664       |
|   |   |    |   | Filing Date              | 7/31/2003        |
|   |   |    |   | First Named Inventor     | Heinz-Josef Lenz |
|   |   |    |   | Art Unit                 | 1634             |
|   |   |    |   | Examiner Name            | Carla J. Myers   |
| Sheet   | 3 | of | 3 | Attorney Docket Number   | 064189-0604      |

| NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
| /CM/                            | D43                   | STOEHLMACHER et al. (2004) "A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer" British J. Cancer <b>91</b> :344-354                                |                |
| /CM/                            | D44                   | SUK et al. (2005) "Polymorphisms in ERCC1 and Grade 2 or 4 Toxicity in Non-Small Cell Lung Cancer Patients" Clin. Cancer Res. <b>11</b> :1534-1538   |                |
| /CM/                            | D45                   | TIBALDI et al. (2008) "Correlation of CDA, ERCC1, and XPD polymorphisms with Response and Survival in Gemcitabine/Cisplatin - Treated Advanced Non-Small Cell Lung Cancer Patients" Clin. Cancer Res. <b>14</b> (6):1797-1803                                  |                |
| /CM/                            | D46                   | ZHOU et al. (2004) "Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy" Clin. Cancer Res. <b>10</b> :4939-4943                      |                |

|                    |               |                 |            |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Carla Myers/ | Date Considered | 04/01/2009 |
|--------------------|---------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.